UNSPSC 51433605: Ketanserin tartrate

This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 645498QK7H, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (1:1) but more generally known as ketanserin tartrate, which bears US NIH Compound Identifier 135348.

UNSPSC 51433605 Ketanserin tartrate is a Commodity code representing pharmaceutical active pharmaceutical ingredients and finished medications procured by state and local health systems, emergency services, and pharmacy benefit programs. State and local buyers under this code acquire medications for emergency medical services, institutional pharmacy programs, and statewide health benefit initiatives, with procurement structured around specific drug formulations, dosage strengths, packaging units, and supply-chain compliance requirements. Issuing bodies include city fire and rescue departments, state health and human services agencies administering pharmacy benefits, and multistate cooperative purchasing alliances coordinating drug procurement across member jurisdictions. The work involves sealed competitive bidding on named pharmaceutical products with firm pricing, supplier certification of manufacturing standards and expiration dating, and warranty obligations for product integrity and timely replacement of expired stock.

Recent activity spans Florida, Texas, and Minnesota through cooperative purchasing vehicles. The City of Tampa Fire Rescue issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications including specific quantities of Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials, with a $40,000 estimated value, nine-month minimum shelf life, ten-day delivery, and a Small Local Business Enterprise 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential evolution toward alternative supply models. The Minnesota Department of Administration, through the Multistate Cooperative Purchasing Alliance, solicited generic multi-source pharmaceuticals and OTC products (S1070000015802) with a March 26, 2026 response date, requiring vendors to supply through three authorized wholesalers with cGMP and Drug Supply Chain Security Act certification, pricing competitiveness weighted at 75 percent of evaluation, and contract terms of two years effective July 1, 2026 for new vendors, with optional extensions and incumbent amendments running through June 30, 2028.